Survival outcome after a second malignancy
| Second malignancy . | No. . | 5-year survival estimate (%) . | 95% CI . | Median survival, y . |
|---|---|---|---|---|
| All sites | 181 | 38.1 | (29.7-46.5) | 3.2 |
| Acute leukemia | 23 | 4.9 | (0.0-14.2) | 0.4 |
| Non-Hodgkin lymphoma | 24 | 49.6 | (28.0, 71.2) | 2.4 |
| Solid tumors | 131 | 42.1 | (31.6, 52.5) | 4.3 |
| Breast | 39 | 76.1 | (57.4-94.8) | Not yet reached |
| Lung | 22 | 0.0 | — | 1.0 |
| Gastrointestinal | 24 | 12.4 | (0-28.1) | 1.9 |
| Sarcoma | 11 | 14.4 | (0-40.2) | 4.3 |
| Genitourinary | 11 | 81.8 | (59.0-100.0) | Not yet reached |
| Head and neck | 7 | 38.1 | (0-77.2) | 2.9 |
| Melanoma | 7 | 80.0 | (44.9-100) | Not yet reached |
| Thyroid | 5 | 100.0 | — | Not yet reached |
| Gynecological | 4 | 50.0 | (1.0-99.0) | 1.4 |
| Second malignancy . | No. . | 5-year survival estimate (%) . | 95% CI . | Median survival, y . |
|---|---|---|---|---|
| All sites | 181 | 38.1 | (29.7-46.5) | 3.2 |
| Acute leukemia | 23 | 4.9 | (0.0-14.2) | 0.4 |
| Non-Hodgkin lymphoma | 24 | 49.6 | (28.0, 71.2) | 2.4 |
| Solid tumors | 131 | 42.1 | (31.6, 52.5) | 4.3 |
| Breast | 39 | 76.1 | (57.4-94.8) | Not yet reached |
| Lung | 22 | 0.0 | — | 1.0 |
| Gastrointestinal | 24 | 12.4 | (0-28.1) | 1.9 |
| Sarcoma | 11 | 14.4 | (0-40.2) | 4.3 |
| Genitourinary | 11 | 81.8 | (59.0-100.0) | Not yet reached |
| Head and neck | 7 | 38.1 | (0-77.2) | 2.9 |
| Melanoma | 7 | 80.0 | (44.9-100) | Not yet reached |
| Thyroid | 5 | 100.0 | — | Not yet reached |
| Gynecological | 4 | 50.0 | (1.0-99.0) | 1.4 |
CI indicates confidence interval.